BLA 021484 · Ferring
Bravelle
Urofollitropin · Subcutaneous
Last checked: Nov 20, 2026Latest source record: Dec 19, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Dec 19, 2002
Approved uses
1
Original approval plus efficacy supplements
Registered trials
24
6 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BRAVELLE · UROFOLLITROPIN 0.9% · Injectable, Subcutaneous · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Urofollitropin" as an intervention, any sponsor and status, largest first.
Lund UniversityAcademic, hospital or other
NCT03737253 · 810 participants · Start Sep 2016 · Primary completion Dec 31, 2021
Drug: Follitropin alpha; Menotropin · For: Female Infertility
Sites: Poznan, Poland; Malmö, Sweden
- FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)Pivotal-lookingCompleted
IBSA Institut Biochimique SAIndustry
NCT01969201 · 710 participants · Start Jan 2014 · Primary completion Jun 2016
Drug: Urofollitrophin; Follitrophin alpha · For: Infertility
Sites: Brussels, Belgium; Brescia, Italy; Milan, Italy · 16 sites in all
- Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization CyclePivotal-lookingCompleted
Clinique OvoIndustry
NCT00971152 · 366 participants · Start Sep 2009 · Primary completion Oct 2013
Drug: menotropins for injection; urofollitropin for injection · For: Subfertility
Sites: Montreal, Canada
- SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile WomenPivotal-lookingCompleted
Merck KGaA, Darmstadt, GermanyIndustry
NCT01185782 · 300 participants · Start Feb 2007 · Primary completion Dec 2007
Drug: Gonalef® (Follitropin alfa); Purified pituitary gonadotropin (Fertinorm-P®) · For: Infertility; Ovulation Induction
Sites: Tokyo, Japan
- Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) ProgramPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT01922193 · 263 participants · Start Oct 2013 · Primary completion Feb 2015
Drug: Highly Purified Urofollitropin; Recombinant Human Follitropin Alfa · For: Infertility
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 11 sites in all
- Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized TrialPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00854373 · 232 participants · Start Jun 1, 2007 · Primary completion Apr 20, 2010
Drug: Bravelle(follicle stimulating hormone) · For: Infertility
Sites: San Francisco, California
- Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese FemalesPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT01923194 · 215 participants · Start Oct 2013 · Primary completion Jul 2015
Drug: Highly Purified Urofollitropin; Recombinant Human Follitropin Alfa · For: Anovulation
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 12 sites in all
- Pregnancy/Implantation Rates Using a Day 3 Score Versus Graduated Embryo Score Plus a Biochemical Marker (sHLA-G)Pivotal-lookingCompleted
University of StellenboschAcademic, hospital or other
NCT00680238 · 214 participants · Start Jun 2004 · Primary completion Jun 2007
Drug: Human derived FSH · For: Infertility
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Gonadotropins for ovulation induction in women with polycystic ovary syndrome.
Weiss NS, Kostova EB, Mol BWJ, et al. · Cochrane Database Syst Rev 2025 · Systematic Review, Meta-Analysis
- Gonadotrophins for ovulation induction in women with polycystic ovary syndrome.
Weiss NS, Kostova E, Nahuis M, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A prospective, randomized study comparing morning to evening administration of gonadotropins in ART.
Sharara FI, Mouhayar Y, Goodwin M, et al. · J Assist Reprod Genet 2018 · Randomized Controlled Trial
- Evaluation of mixed protocols with Bravelle (human-derived FSH) and Repronex (hMG) to assess clinical efficacy (EMBRACE) in women undergoing in vitro fertilization.
Keye WR, Marrs RP, Check JH, et al. · Fertil Steril 2004 · Clinical Trial, Comparative Study
- [Clinical efficacy of Xuanju compound capsule combined with urofollitropin in the treatment of patients with idiopathic oligoasthenozoospermia].
Zhao YY, Chen LS, Wei W, et al. · Zhonghua Nan Ke Xue 2023 · Controlled Clinical Trial, English Abstract
- Comparison of the efficacy and safety of a highly purified human follicle-stimulating hormone (Bravelle) and recombinant follitropin-beta for in vitro fertilization: a prospective, randomized study.
Dickey RP, Thornton M, Nichols J, et al. · Fertil Steril 2002 · Clinical Trial, Comparative Study
Sponsor: Ferring
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.